A new research paper was published in Oncotarget's Volume 13 on December 29, 2022, entitled, “Impact of Covid-19 on the management of patients with metastatic melanoma.”
The Covid-19 pandemic created new uncertainties in the management of metastatic melanoma patients. In particular, the impact of immunotherapy, targeted therapy or chemotherapy on the risk of Sars-CoV-2 infection and severity was debated.
In this study, researchers Michèle Welti, Phil F. Cheng, Joanna Mangana, Mitchell P. Levesque, Reinhard Dummer, and Laurence Imhof from University Hospital Zurich, University of Zurich and ETH Zurich analyzed all patients with metastatic melanoma receiving therapy at the Department of Dermatology at the University Hospital Zürich who developed Covid-19 between February 2020 and February 2022.
“We retrospectively collected demographic data, cancer-specific parameters, melanoma treatment regimen, comorbidities and Covid-19-specific parameters in these patients.”
Of the 350 patients with metastatic melanoma, 25 had Covid-19. The median age at the time of Covid-19 diagnosis was 66 years (range 36–86), 10 patients were female and 15 patients were male. The treatment regimen during infection was immunotherapy in 12 cases, followed by targeted therapy (n = 8), chemotherapy (n = 2) and TVEC injections, follow-up and palliative therapy in 1 case each.
The severity was mild in 17 patients and 8 had a moderate to critical course. Patients with a severe Covid-19 course were often older and had more comorbidities than patients with a mild infection. Many of the patients had a mild Covid-19 course despite having metastatic melanoma and systemic therapy.
“We therefore recommend continuing systemic therapy whenever possible, even in such exceptional situations as the Covid-19 pandemic.”
DOI: https://doi.org/10.18632/oncotarget.28333
Correspondence to: Michèle Welti - michele.welti@uzh.ch
Keywords: metastatic melanoma, Covid-19, Sars-CoV-2, immunotherapy, targeted therapy
About Oncotarget:
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:
Twitter – https://twitter.com/Oncotarget
Facebook – https://www.facebook.com/Oncotarget
YouTube – https://www.youtube.com/@OncotargetJournal
Instagram – https://www.instagram.com/oncotargetjrnl/
LinkedIn – https://www.linkedin.com/company/oncotarget/
Pinterest – https://www.pinterest.com/oncotarget/
LabTube – https://www.labtube.tv/channel/MTY5OA
SoundCloud – https://soundcloud.com/oncotarget
For media inquiries, please contact: media@impactjournals.com.
Oncotarget